home / stock / abeo / abeo news


ABEO News and Press, Abeona Therapeutics Inc.

Stock Information

Company Name: Abeona Therapeutics Inc.
Stock Symbol: ABEO
Market: NASDAQ
Website: abeonatherapeutics.com

Menu

ABEO ABEO Quote ABEO Short ABEO News ABEO Articles ABEO Message Board
Get ABEO Alerts

News, Short Squeeze, Breakout and More Instantly...

ABEO - Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CLEVELAND, Feb. 09, 2026 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced it has granted equity awards to new non-executive employees who joined the Company. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4). On January 31, 2026, the Co...

ABEO - Abeona Therapeutics® Announces Appointment of Mohamad Tabrizi as Chief Business Officer

CLEVELAND, Dec. 15, 2025 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced the appointment of Mohamad Tabrizi, M.S., M.B.A., as Senior Vice President, Chief Business Officer (CBO). In this role, Mr. Tabrizi will lead the Company’s corporate strategy and business d...

ABEO - Abeona Therapeutics® Announces New Qualified Treatment Center for ZEVASKYN® in Texas

CLEVELAND, Dec. 11, 2025 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced activation of The University of Texas Medical Branch (UTMB) in Galveston, Texas, as the newest Qualified Treatment Center (QTC) for the administration of ZEVASKYN (prademagene zamikeracel) gene-mo...

ABEO - Abeona Therapeutics® Announces First Patient Treatment with ZEVASKYN® Gene Therapy

CLEVELAND, Dec. 08, 2025 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced the first commercial patient treatment with FDA-approved ZEVASKYN (prademagene zamikeracel), a first-of-its-kind, autologous gene therapy for treating wounds in adult and pediatric patients with r...

ABEO - Biotech Breakouts, AI Momentum, and Athletic Triumphs- Stocks to Watch as Markets Race Toward the Close

2025-11-12 15:50:17 ET DENVER, Colo., Nov 12, 2025 ( 247marketnews.com )- The final trading hour of Wednesday’s session is shaping up to be a sprint to the finish line as investors pile into biotech, AI, and clean-tech names on strong earnings, corporate catalysts, and heavy...

ABEO - Abeona Therapeutics Q3 2025: Strong Financials And Zevaskyn Launch Ahead

2025-11-12 14:52:18 ET Thesis Abeona Therapeutics Inc. ( ABEO ) reported some pretty attractive figures for 3Q25, and the stock is already up 22% post announcement. GAAP EPS came in at just -$0.10, beating expectations by $0.18. The company also ended the quarter with a heft...

ABEO - Abeona anticipates 2026 profitability as ZEVASKYN demand doubles and QTC network expands

2025-11-12 12:12:39 ET More on Abeona Therapeutics Abeona Therapeutics Inc. (ABEO) Q3 2025 Earnings Call Transcript Abeona Therapeutics: Zevaskyn Data Key In Gauging Momentum - Why I Hold Abeona Therapeutics Inc. (ABEO) Q2 2025 Earnings Call Transcript Abeona...

ABEO - Abeona Therapeutics Inc. (ABEO) Q3 2025 Earnings Call Transcript

2025-11-12 12:11:36 ET Abeona Therapeutics Inc. (ABEO) Q3 2025 Earnings Call November 12, 2025 8:30 AM EST... Read the full article on Seeking Alpha For further details see: Abeona Therapeutics Inc. (ABEO) Q3 2025 Earnings Call Transcript

ABEO - Here's Why Abeona Therapeutics Popped Higher Today

2025-11-12 11:37:50 ET Abeona Therapeutics (NASDAQ: ABEO) stock soared by more than 25% as of 10 a.m. today. The reason for the surging share price is a strong set of third-quarter earnings and a very positive update on its Recessive Dystrophic Epidermolysis Bullosa (RDEB) treatment...

ABEO - Abeona Therapeutics GAAP EPS of -$0.10 beats by $0.18

2025-11-12 07:33:36 ET More on Abeona Therapeutics Abeona Therapeutics: Zevaskyn Data Key In Gauging Momentum - Why I Hold Abeona Therapeutics Inc. (ABEO) Q2 2025 Earnings Call Transcript Abeona Therapeutics: AAV204 Capsid Could Be Next Growth Prospect Beyond Zevasky...

Next 10